Literature DB >> 25981840

Immediate-type hypersensitivity reactions due to antituberculosis drugs: a successful readministration protocol.

Gözde Köycü Buhari1, Metin Keren2, Adile Berna Dursun3, Müjgan Güler4, Güngör Dulkar4, Nilgün Kalaç4, Şeref Özkara4, Ferda Öner Erkekol2.   

Abstract

BACKGROUND: Little is known about drug hypersensitivity reactions from antituberculosis drugs.
OBJECTIVE: To determine the frequency, risk factors, and characteristics of immediate-type hypersensitivity reactions from first-line antituberculosis drugs and to evaluate the usefulness of a readministration protocol for culprit drugs in this group of patients.
METHODS: The study population consisted of patients with tuberculosis who were hospitalized and treated in the authors' hospital in 2011. Demographics and disease and treatment characteristics of patients with immediate-type hypersensitivity from antituberculosis drugs were compared with the other patients. Culprit drugs were readministered gradually according to a defined protocol to patients with immediate-type hypersensitivity.
RESULTS: Tree hundred seventy-nine patients were included in the study. Eighteen immediate-type hypersensitivity reactions were detected in 13 patients (3.43%). The only identified risk factor was female sex (odds ratio 4.085). Isoniazid, rifampicin, pyrazinamide, and ethambutol were readministered in 11 patients and rifampicin was readministered in 2 patients, with 6- to 8-step protocols for each drug. Only in 2 patients did allergic reactions with rifampicin develop during the procedure. In these patients, after treatment and complete remission of allergic symptoms, the last tolerated dose was administered and the protocol was completed with the same adjustments.
CONCLUSION: Immediate-type allergic reactions from antituberculosis drugs are not rare and not related to disease or treatment characteristics. The protocols used in this study provide a useful and safe method for readministration of culprit drugs to patients with antituberculosis drug hypersensitivity.
Copyright © 2015 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25981840     DOI: 10.1016/j.anai.2015.04.015

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  3 in total

1.  Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco.

Authors:  Mariam El Hamdouni; Samir Ahid; Jamal Eddine Bourkadi; Jouda Benamor; Mohammed Hassar; Yahia Cherrah
Journal:  Infection       Date:  2019-06-04       Impact factor: 7.455

2.  Severe Cutaneous Adverse Reactions to Anti-tuberculosis Drugs in Korean Patients.

Authors:  Hyun Jung Jin; Dong Yoon Kang; Young Hee Nam; Young Min Ye; Young Il Koh; Gyu Young Hur; Sae Hoon Kim; Min Suk Yang; Sujeong Kim; Yi Yeong Jeong; Min Hye Kim; Jeong Hee Choi; Hye Ryun Kang; Eun Jung Jo; Hye Kyung Park
Journal:  Allergy Asthma Immunol Res       Date:  2021-03       Impact factor: 5.764

3.  Versatile TLC-Densitometric Methods for the Synchronous Estimation of Cinnarizine and Acefylline Heptaminol in The Presence of Potential Impurity and Their Reported Degradation Products.

Authors:  Ola M El-Houssini; Mohammad A Mohammad
Journal:  J Chromatogr Sci       Date:  2021-12-08       Impact factor: 1.618

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.